Milestone Scientific Q2 revenue rises 22% on medical segment growth, reaffirms 2026 outlook

Milestone Scientific

14/08/2026 12:42

Overview
Medical device maker's Q2 revenue rose 22% yr/yr, driven by dental and medical segment growth
Medical segment revenue grew 231% yr/yr, reflecting increased CompuFlo adoption and reimbursement progress
Net loss narrowed to $1.1 mln from $1.5 mln a year ago

Outlook
Milestone Scientific reaffirms 2026 revenue outlook of $9.8 mln to $10.2 mln
Company expects CompuFlo revenue to grow faster than overall business in 2026
Company says Q3 revenue may be lower due to seasonality and fewer large international orders

Result Drivers
COMPUFLO ADOPTION - Co said medical segment growth was driven by increased physician adoption and progress on reimbursement for CompuFlo
DENTAL SEGMENT - Co said dental product sales contributed to revenue growth in Q2
INTERNATIONAL ORDERS - Co said Q2 revenue benefited from two large international orders, which are not expected to recur in Q3

Company press release: ID:nGNX8pqQyq

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$2.80 mln
$2.70 mln (2 Analysts)
Q2 Loss Per Share
 
$0.01
 
Q2 Net Loss
 
$1.10 mln
 
Q2 Gross Profit
 
$1.90 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Milestone Scientific Inc is $1.00, about 80.8% above its August 13 closing price of $0.55

Reuters Recommended Reads
Aug 13 - Heartflow Q2 revenue rises 48%, lifts 2026 outlook
Aug 12 - Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Aug 13 - India's Max Healthcare posts quarterly profit rise on strong demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)